Abstract:Importance: Epilepsy is the most common neurological disorder of childhood. Identifying genetic diagnoses underlying epilepsy is critical to developing effective therapies and improving outcomes. Most children with non-acquired (unexplained) epilepsy remain genetically unsolved, and the utility of genome sequencing after nondiagnostic exome sequencing is unknown. Objective: To determine the diagnostic (primary) and clinical (secondary) utility of genome sequencing after nondiagnostic exome sequencing in individuals with unexplained pediatric epilepsy. Design: This cohort study performed genome sequencing and comprehensive analyses for 125 participants and available biological parents enrolled from August 2018 to May 2023, with data analysis through April 2024 and clinical return of diagnostic and likely diagnostic genetic findings. Clinical utility was evaluated. Setting: Pediatric referral center Participants: Participants with unexplained pediatric epilepsy and previous nondiagnostic exome sequencing; biological parents when available Exposure(s): Short-read genome sequencing and analysis Main Outcome(s) and Measure(s): Primary outcome measures were the diagnostic yield of genome sequencing, defined as the percentage of participants receiving a diagnostic or likely diagnostic genetic finding, and the unique diagnostic yield of genome sequencing, defined as the percentage of participants receiving a diagnostic or likely diagnostic genetic finding that required genome sequencing. The secondary outcome measure was clinical utility of genome sequencing, defined as impact on evaluation, treatment, or prognosis for the participant or their family. Results: 125 participants (58 [46%] female) were enrolled with median age at seizure onset 3 [IQR 1.25, 8] years, including 44 (35%) with developmental and epileptic encephalopathies. The diagnostic yield of genome sequencing was 7.2% (9/125), with diagnostic genetic findings in five cases and likely diagnostic genetic findings in four cases. Among the solved cases, 7/9 (78%) required genome sequencing for variant detection (small copy number variant, three noncoding variants, and three difficult to sequence small coding variants), for a unique diagnostic yield of genome sequencing of 5.6% (7/125). Clinical utility was documented for 4/9 solved cases (44%). Conclusions and Relevance: These findings suggest that genome sequencing can have diagnostic and clinical utility after nondiagnostic exome sequencing and should be considered for patients with unexplained pediatric epilepsy.

Clinical utility of a genetic diagnosis in individuals with cerebral palsy and related motor disorders

Genetic investigations in cerebral palsy

Exome sequencing reveals genetic heterogeneity and clinically actionable findings in children with cerebral palsy

The Genetic Puzzle of Cerebral Palsy: Results of a Monocentric Study

Clinical characteristics suggestive of a genetic cause in cerebral palsy: A systematic review

Comprehensive whole-genome sequence analyses provide insights into the genomic architecture of cerebral palsy

Genetic Spectrum Identified by Exome Sequencing in a Chinese Pediatric Cerebral Palsy Cohort

Clinical exome sequencing in the diagnosis of pediatric neuromuscular disease

Enhanced utility of family-centered diagnostic exome sequencing with inheritance model–based analysis: results from 500 unselected families with undiagnosed genetic conditions

Utility of genome sequencing in exome‐negative pediatric patients with neurodevelopmental phenotypes

The utility of exome sequencing in diagnosing pediatric neurodevelopmental disorders in a highly consanguineous population

Diagnostic and Clinical Utility of Whole Genome Sequencing in a Cohort of Undiagnosed Chinese Families with Rare Diseases

Spectrum of Leukodystrophy and Genetic Leukoencephalopathy in Indian Population Diagnosed by Clinical Exome Sequencing and Clinical Utility

Utility of Genome Sequencing After Nondiagnostic Exome Sequencing in Unexplained Pediatric Epilepsy

Developmental and epileptic encephalopathy: Personal utility of a genetic diagnosis for families

C.1 Utility of genetic testing in the pre-surgical evaluation of children with drug-resistant epilepsy

Characterization of Clinical MRI Findings in Moderately-Late Preterm Infants Diagnosed with Cerebral Palsy: A Single Center Retrospective Study

Parental attitudes and experiences in pursuing genetic testing for their child's motor speech disorder

Utility of genetic testing in the pre-surgical evaluation of children with drug-resistant epilepsy

Clinical Utility of Rapid Exome Sequencing Combined With Mitochondrial DNA Sequencing in Critically Ill Pediatric Patients With Suspected Genetic Disorders

Clinical genomics expands the morbid genome of intellectual disability and offers a high diagnostic yield